Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
1.1Antibody production by cell fusion
What ifWhat if a human hybridoma produces the anti-amyloid beta antibody through cell fusion and clonal selection?
An antibody-secreting human B cell is fused with a human myeloma fusion partner to form a hybridoma. A single clone selected for binding aggregated amyloid beta secretes the antibody into culture medium for purification.
1.1Humanized antibody with donor loops
What ifWhat if the recombinant antibody uses nonhuman binding loops in human antibody frameworks?
The heavy- and light-chain binding loops from a mouse anti-amyloid beta antibody are grafted onto human variable-region frameworks. The expressed antibody binds aggregated amyloid beta through the grafted loops.
1.1Polyclonal antibodies against amyloid beta
What ifWhat if an affinity-purified polyclonal antibody fraction supplies the amyloid beta binding activity?
Immobilized amyloid beta captures reactive immunoglobulins from pooled human plasma, and elution recovers the bound fraction. Antibodies from multiple B-cell lineages bind a range of epitopes on amyloid beta.
1.1Antibody targeting extracellular tau
What ifWhat if the antibody binds extracellular tau aggregates and scyllo-inositol supplies the amyloid-directed component?
The antibody binds extracellular tau assemblies involved in seeded aggregation, and a cell-based assay measures whether binding reduces seeding. Scyllo-inositol is evaluated separately for its effect on amyloid beta assembly.
1.1Small molecule targeting soluble amyloid
What ifWhat if oral tramiprosate supplies the small-molecule component alongside the anti-amyloid beta antibody?
Claim language“amount of scyllo-inositol”
Tramiprosate is an aminopropanesulfonate that interacts with soluble amyloid beta and suppresses oligomer formation in aggregation assays. The antibody binds aggregated amyloid beta, so the two components act on different stages of assembly.
Section 2 · machine-generated
Variations
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
Other field of use
Combination exposure in a tissue assay
An in vitro pharmacology assay exposes human neuron and microglia cocultures to amyloid beta aggregates, a recombinant fully human anti-amyloid beta monoclonal antibody, and scyllo-inositol. Separate wells receive the combination, either component alone, or vehicle. Imaging quantifies extracellular aggregate burden and microglial uptake at matched time points across the four conditions.
Component substitution
Fab substitution in an aggregation assay
A recombinant antigen-binding fragment replaces the intact monoclonal antibody and retains its heavy-chain and light-chain variable regions. The fragment and scyllo-inositol are added to wells containing synthetic amyloid beta. Aggregate size is measured by size-exclusion chromatography, and intact-antibody control wells are matched for antigen-binding-site concentration.
Parameter or scale variation
Timed addition in a plate assay
A 96-well plate contains amyloid beta in matched wells for simultaneous and sequential addition of the antibody and scyllo-inositol. Sequential conditions introduce the second component 2, 6, or 24 hours after the first and include both orders of addition. Samples are collected 48 hours after the first addition, with buffer additions matched across conditions to maintain a common final volume.
Combination with existing systems
Combination monitoring through electronic health records
An electronic health record links antibody administration events, reported scyllo-inositol intake, brain imaging reports, and cognitive assessments by patient identifier. The system records antibody administrations as timestamped events and scyllo-inositol intake as reported start and stop dates. A timeline displays exposure periods beside assessments for clinician review.
Combination binding measurements under continuous flow
A surface plasmon resonance instrument carries immobilized amyloid beta on a sensing channel and uses a second channel as a reference. The instrument equilibrates both channels with buffer containing scyllo-inositol, injects antibody prepared in the same buffer, and records binding and dissociation. A matched run uses buffer alone to measure antibody binding kinetics in the absence of scyllo-inositol.
Automated or data-driven variant
Automated measurement of amyloid aggregate burden
An automated fluorescence microscope images amyloid beta aggregates in wells exposed to the antibody, scyllo-inositol, or their combination. Image-analysis software subtracts background, segments aggregates using a threshold set from control wells, and calculates aggregate count and area per field. The software links these measurements to treatment conditions through plate and well identifiers.
Specific version of a part
Protofibril-binding human immunoglobulin
Mammalian production cells express recombinant human heavy and light chains that assemble into an immunoglobulin G1 antibody. A binding assay compares its affinity for soluble amyloid beta protofibrils with its affinity for monomeric amyloid beta.
Immediate-release scyllo-inositol tablet
A compressed tablet contains scyllo-inositol, microcrystalline cellulose, and a disintegrant that promotes breakup after swallowing. The patient takes the tablet orally and receives the antibody by intravenous infusion.
Section 3 · quoted from USPTO records
Other work
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
1.1administering a pharmaceutically effective amount of a recombinant, fully human, anti-amyloid beta monoclonal antibody and a pharmaceutically effective amount of scyllo-inositol.
A method of treating a subject who has developed an anti-antibody response to a first human or humanized monoclonal antibody, the method comprising administering to the subject a second human or humanized monoclonal antibody having a variable region identical to the first monoclonal antibody but a different allotypic phenotype than the first monoclonal antibody.
A · US 2011/0070230 A1 · claim 1
Examples of β-amyloid aggregation inhibitors and β-amyloid immunotherapies include PBT2 (Prana Biotechnology), ELND005/AZD-103 (Elan and Transition Therapeutics), Gammagard/IGIV (Baxter International), monoclonal antibody LY2062430 (Eli Lilly), and bapineuzumab (Wyeth/Elan).
B · US 2015/0320742 A1 · ¶ 22
An empty cell means only that no passage was reproduced there.
Statements in these documents
Despite this, because of the large amount of genetic variation in the human population, human-anti-human Ab (HAHA) responses will prove difficult to eliminate.
A · US 2011/0070230 A1 · ¶ 6
The invention relates to the development of methods and compositions that reduce the likelihood that a subject will develop an anti-Ab response to an administered Ab.
A · US 2011/0070230 A1 · ¶ 7
The present application relates to new uses of 5-HT6 receptor antagonists, specifically 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline, and to the combination of 5-HT6 receptor antagonists, specifically 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline, with a second therapeutic agent.
B · US 2015/0320742 A1 · ¶ 2
Cite aspatent.fyi, US 2026/0355128 A1, claim 1, first published 2026-11-19T08:28:42-05:00, https://patent.fyi/US20260355128/, SHA-256 bc54fbc52bfd6de33859e3bce65587d63bafe4a9cd162a3d066338b348ea8866